styled-text

NOW APPROVED

text-color-black
style
marigold
hero-secondary
gradient-background

Recommended prophylaxis

Prophylaxis can help reduce the risk of moderate to severe dermatologic reactions.1

style
cobalt
styled-text

Initiate prophylactic measures prior to the first dose to reduce the risk of moderate to severe dermatologic reactions1

margin-top-lg
text-color-corazon
styled-text
Prophylactic and proactive dermatologic reaction management is important to support patients1*
margin-top-sm
margin-bottom-sm
text-color-denim-blue
styled-text
Monitor for signs and symptoms and treat as medically appropriate.
margin-bottom-sm
text-color-90-black
spacing-lg
mobile-spacing-sm
grid
plus
Topical corticosteroids
Topical corticosteroids1-3
  • Face: eg, hydrocortisone 2.5% BID
  • Chest: eg, triamcinolone 0.1% BID
Emollient
Emollient cream1-3
  • Fragrance-free, emollient moisturizing cream
Sunscreen
Sunscreen1-4
  • SPF ≥30 applied ≥30 minutes before sun exposure. Advise patients to reapply every 2 hours
Oral antibiotics
Oral antibiotics1-3

Consider:

  • Eg, doxycycline 100 mg BID
or minocycline 50 mg BID
  • Initiate prior to first dose of RASONQUE and as clinically indicated throughout treatment
spacing-lg
mobile-spacing-sm
styled-text
  • Advise patients to limit sun exposure and wear protective clothing, including a hat, if they are in the sun5
margin-bottom-lg
mobile-margin-bottom-10
text-color-black
styled-text
  • Median time to first onset of dermatologic toxicity was 13 days (range: 1 to 106 days) in clinical trials of patients with pancreatic adenocarcinoma1†
text-color-90-black
spacing-xl
callout-banner
without-image

Consult the Dosing & Adverse Reaction Management Guide
for additional information

Download
/content/dam/branded-hcp-full/rasonque-dosing-ar-guide.pdf
blue-tint
solid-denim
spacing-xxs
styled-text

*Prophylaxis for dermatologic reactions was recommended but not required in RASolute 302.3

†The pooled safety population of RASONQUE reflects exposure to RASONQUE 300 mg once daily in 241 patients with pancreatic adenocarcinoma enrolled in RASolute 302 and 184 patients with pancreatic adenocarcinoma enrolled in the open‑label trial RMC-6236-001.1

text-color-black
spacing-xl
RASONQUE dosing
/content/branded-hcp-full/dosing/rasonque-dosing
Patient access support
/content/branded-hcp-full/support/patient-access-support
spacing-sm
mobile-spacing-sm
styled-text
BID=twice a day; SPF=sun protection factor.
text-color-black
/content/branded-hcp-full/isi-block
expandable
true
expandable-title
Expand
identifier
isi
spacing-lg
mobile-spacing-lg
styled-text
References: 1. RASONQUE. Prescribing information. Revolution Medicines, Inc.; 2026. 2. Data on file. Revolution Medicines, Inc.; 2026. 3. Protocol for: O’Reilly EM, Wainberg ZA, Hendifar AE, et al; RASolute 302 Trial Investigators. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. Published online May 31, 2026. doi:10.1056/NEJMoa2605555 4. Kaminsky A, Suhl S, Sacknovitz Y, Schwartz GK, Deverapalli S, Geskin LJ. Skin health in oncology: evidence-based skin care for cancer patients. Oncologist. 2026;31(7):oyag194. doi:10.1093/oncolo/oyag194 5. RASONQUE. Medication guide. Revolution Medicines, Inc.; 2026.
margin-bottom-none
text-color-black
spacing-xl
mobile-spacing-xl